Compare · AYLA vs CSL
AYLA vs CSL
Side-by-side comparison of Ayala Pharmaceuticals Inc. (AYLA) and Carlisle Companies Incorporated (CSL): market cap, price performance, sector, and recent activity on the wire.
Summary
- AYLA operates in Consumer Discretionary, while CSL operates in Industrials - the two are in different parts of the market.
- CSL is the larger of the two at $13.91B, about 185.2x AYLA ($75.1M).
- CSL has hit the wire 6 times in the past 4 weeks while AYLA has been quiet.
- CSL has more recent analyst coverage (16 ratings vs 5 for AYLA).
- Company
- Ayala Pharmaceuticals Inc.
- Carlisle Companies Incorporated
- Price
- $0.56+11.00%
- $343.80+0.80%
- Market cap
- $75.1M
- $13.91B
- 1M return
- -
- -0.59%
- 1Y return
- -
- -4.03%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 5
- 16
Ayala Pharmaceuticals Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Carlisle Companies Incorporated
Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products in the United States, Europe, Asia, Canada, Mexico, the Middle East, Africa, and internationally. It operates through four segments: Carlisle Construction Materials, Carlisle Interconnect Technologies, Carlisle Fluid Technologies, and Carlisle Brake & Friction. The Carlisle Construction Materials segment produces building envelopes for commercial, industrial, and residential buildings, including single-ply roofing products, rigid foam insulations, spray polyurethane foam, architectural metal products, heating, ventilation and air conditioning hardware and sealants, waterproofing products, and air and vapor barrier systems. The Carlisle Interconnect Technologies segment produces wires and cables for the commercial aerospace, military and defense electronics, medical device, industrial, and test and measurement markets. It also offers sensors, connectors, contacts, cable assemblies, complex harnesses, racks, trays, and installation kits, as well as engineering and certification services. The Carlisle Fluid Technologies segment produces engineered liquid products, powder products, sealants and adhesives finishing equipment, and integrated system solutions for spraying, pumping, mixing, metering, and curing of coatings used in the automotive manufacture, general industrial, protective coating, wood, and specialty and automotive refinishing markets. The Carlisle Brake & Friction segment provides duty brakes, and clutch and transmission products for the construction, agriculture, mining, aircraft, on-highway, and other industrial markets. The company sells its products under the Carlisle, Binks, DeVilbiss, Ransburg, BGK, MS Powder, Hawk, Wellman, Thermax, Tri-Star, LHi Technology, Providien, SynTec, Weatherbond, Hunter Panels, Resitrix, Hertalan, Insulfoam, and Velvetouch brands. Carlisle Companies Incorporated was founded in 1917 and is headquartered in Scottsdale, Arizona.
Latest AYLA
- SEC Form 3 filed by new insider Martell Bridget A
- SEC Form 3 filed by new insider Orbach Pini
- SEC Form 3 filed by new insider Golan Roy
- SEC Form 10-K filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.
- SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)
- SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.
- Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets
- SEC Form 4: Amoon Growth Fund Limited Partnership returned 2,991,473 shares to the company
Latest CSL
- SEC Form 4 filed by Director Palmer Sheryl
- SEC Form 4 filed by Director Singh Jesse G
- SEC Form 4 filed by Director Ricard Corrine D.
- SEC Form 4 filed by Director Hansen Maia
- SEC Form 4 filed by Director Frias James D
- SEC Form SD filed by Carlisle Companies Incorporated
- SEC Form SCHEDULE 13G filed by Carlisle Companies Incorporated
- Director Collins Jonathan R. converted options into 5,902 shares, increasing direct ownership by 189% to 9,029 units (SEC Form 4)
- Carlisle Companies Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Carlisle Companies Announces Fourth Employee Stock Option Grant Since 2009